

Diluk R W Kannangara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7881516/publications.pdf>

Version: 2024-02-01

18
papers

449
citations

933447

10
h-index

888059

17
g-index

18
all docs

18
docs citations

18
times ranked

768
citing authors

#	ARTICLE	IF	CITATIONS
1	Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4894-4901.	2.4	7
2	Expanding the role of Australian community dietitians in gout management. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 1402-1408.	1.9	1
3	Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout. <i>Current Rheumatology Reports</i> , 2018, 20, 47.	4.7	5
4	Individualising the dose of allopurinol in patients with gout. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2015-2026.	2.4	17
5	Allopurinol: insights from studies of dose-response relationships. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 449-462.	3.3	21
6	Mobile applications to enhance self-management of gout. <i>International Journal of Medical Informatics</i> , 2016, 94, 67-74.	3.3	33
7	Xanthine oxidoreductase and its inhibitors: relevance for gout. <i>Clinical Science</i> , 2016, 130, 2167-2180.	4.3	31
8	Barriers to Care in Gout: From Prescriber to Patient. <i>Journal of Rheumatology</i> , 2016, 43, 144-149.	2.0	53
9	Effect of xanthine oxidase inhibitors on the renal clearance of uric acid and creatinine. <i>Clinical Rheumatology</i> , 2016, 35, 2375-2376.	2.2	2
10	Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1363-1366.	0.9	30
11	The Toll-Like Receptor 4 (TLR4) Variant rs2149356 and Risk of Gout in European and Polynesian Sample Sets. <i>PLoS ONE</i> , 2016, 11, e0147939.	2.5	31
12	Understanding and improving the use of allopurinol in a teaching hospital. <i>Internal Medicine Journal</i> , 2015, 45, 383-390.	0.8	4
13	Hypouricemic Effects of Prednisone and Allopurinol: An Uneven Playing Field?. <i>Canadian Journal of Cardiology</i> , 2014, 30, 376.e1.	1.7	1
14	Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950-2012. <i>Drug Safety</i> , 2013, 36, 953-980.	3.2	145
15	Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 932-938.	2.4	33
16	An Audit of a Therapeutic Drug Monitoring Service for Allopurinol Therapy. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 863-866.	2.0	0
17	Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients. <i>Arthritis Research and Therapy</i> , 2012, 14, R189.	3.5	32
18	Oxypurinol, allopurinol and allopurinol-ribose in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 828-829.	2.4	3